SpringWorks Therapeutics, Inc. SWTX
Set alert
46.99 0.00 0.00%
At close · Jul 1
46.99 Day range 46.99
52-week range unavailable
- Open
- 46.99
- Prev close
- 46.99
- Mkt cap
- 3.54B
- Vol
- 5.01M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 46.99
- High
- 46.99
- Forward P/E
- -21.96
- Beta
- 0.70
- Short ratio
- 1.46
- Inst. own
- 87.40%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 46.50
- 200-d avg
- 41.63
- 1y target
- 47.00
Financial health
Altman Z-Score
20.07 Safe zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
3 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
Valuation
P/E -10.4×
FY 2017 5y median -10.4× FY 2024
P/S 14.0×
FY 2017 5y median 89.7× FY 2024
P/B 5.6×
FY 2017 5y median 5.6× FY 2024
P/FCF -14.9×
FY 2017 5y median -14.9× FY 2024
EV/EBITDA -9.5×
FY 2017 5y median -9.5× FY 2024
EV/Sales 13.7×
FY 2017 5y median 85.6× FY 2024
FCF Yield -6.7%
FY 2017 5y median -6.7% FY 2024
Profitability
Gross Margin 93.4%
FY 2017 5y median 92.3% FY 2024
Operating Margin -145.2%
FY 2017 5y median -145.2% FY 2024
Net Margin -134.7%
FY 2017 5y median -134.7% FY 2024
ROE -53.7%
FY 2017 5y median -49.7% FY 2024
ROIC -56.9%
FY 2017 5y median -48.4% FY 2024
ROA -44.0%
FY 2017 5y median -44.0% FY 2024
Growth (YoY)
Revenue 3417.3%
FY 2017 FY 2024
Operating Income 18.9%
FY 2017 FY 2024
EPS (diluted) 32.4%
FY 2017 FY 2024
Free Cash Flow 21.8%
FY 2017 FY 2024
Financial Health
Current Ratio 3.8×
FY 2017 5y median 11.7× FY 2024
Quick Ratio 3.7×
FY 2017 5y median 11.7× FY 2024
Debt / Equity 0.0×
FY 2017 5y median 0.0× FY 2024
Net Debt / EBITDA 0.2×
FY 2017 5y median 0.5× FY 2024
Interest Coverage 0.0×
FY 2017 5y median 0.0× FY 2024
Dividends
Dividend Yield 0.0%
FY 2017 5y median 0.0% FY 2024
Payout Ratio 0.0%
FY 2017 5y median 0.0% FY 2024
Annual · latest fiscal year ends 2024-12-31